2026-04-17T07:49:38Zhttps://recercat.cat/oai/requestoai:recercat.cat:10256/124632024-06-18T13:35:30Zcom_2072_452955com_2072_2054col_2072_452958
RECERCAT
author
Balmaña, Meritxell
author
Giménez, Estela
author
Puerta, Angel
author
Llop Escorihuela, Esther
author
Figueras, Joan
author
Fort Martorell, Esther
author
Sanz Nebot, María Victoria
author
Bolòs, Carme de
author
Rizzi, Andreas
author
Barrabés Vera, Sílvia
author
Frutos, Mercedes de
author
Peracaula Miró, Rosa
2024-06-18T13:35:30Z
2024-06-18T13:35:30Z
info:eu-repo/date/embargoEnd/2026-01-01info:eu-repo/date/embargoEnd/2026-01-012016-01-30
http://hdl.handle.net/10256/12463
Pancreatic cancer (PDAC) lacks reliable diagnostic biomarkers and the search for new biomarkers represents an important
challenge. Previous results looking at a small cohort of patients showed an increase in α-1-acid glycoprotein
(AGP) fucosylation in advanced PDAC using N-glycan sequencing. Here,we have analysed AGP glycoforms in a larger
cohort using several analytical techniques includingmass spectrometry (MS), capillary zone electrophoresis (CZE) and
enzyme-linked lectin assays (ELLAs) for determining AGP glycoforms which could be PDAC associated. AGP from 31
serum samples, including healthy controls (HC), chronic pancreatitis (ChrP) and PDAC patients, was purified by immunoaffinity
chromatography. Stable isotope labelling of AGP released N-glycans and their analysis by zwitterionic
hydrophilic interaction capillary liquid chromatography electrospray MS (μZIC-HILIC–ESI-MS) showed an increase
in AGP fucosylated glycoforms in PDAC compared to ChrP and HC. By CZE-UV analysis, relative concentrations of
some of the AGP isoforms were found significantly different compared to those in PDAC and HC. Finally, ELLAs
using Aleuria aurantia lectin displayed a significant increase in AGP fucosylation, before and after AGP neuraminidase
treatment, in advanced PDAC compared to ChrP and HC, respectively. Altogether, these results indicate that α1-3
fucosylated glycoforms of AGP are increased in PDAC and could be potentially regarded as a PDAC biomarkerThis work was supported by the Government of Catalonia (grant 2014 SGR 229), the Spanish Ministry of Science and Innovation (grant BIO 2010-16922, awarded to R. P) and the Spanish Ministry of Economy and Competitiveness (grant CTQ2013-43236, awarded to M.F. and grant CTQ2011-27130, awarded to V. S-N)
Tots els drets reservats info:eu-repo/semantics/embargoedAccess
Pàncrees -- Càncer
Pancreas -- Cancer
Marcadors tumorals
Tumor markers
Increased α1-3 fucosylation of α-1-acid glycoprotein (AGP) in pancreatic cancer
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion